Patents by Inventor Yanqun ZENG

Yanqun ZENG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230096978
    Abstract: The present invention relates to the technical of medicinal chemistry, and specifically relates to a use of a 6-oxaspiro[4.5]decane derivative as an MOR receptor agonist for treating pain and pain-related disorders.
    Type: Application
    Filed: August 5, 2021
    Publication date: March 30, 2023
    Inventors: Yongzhe XIANG, Yanqun ZENG, Ning ZHOU, Ying WANG
  • Patent number: 11447463
    Abstract: The present invention provides a compound of a general formula I, a stereomeride, pharmaceutically acceptable salt or a solvate thereof, a preparation method thereof, and usages in preparing medicines for preventing and/or treating diseases or symptoms caused by drug-resistant tumors or drug-resistant bacteria and in preparing medicines for preventing and/or treating diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection. Preferably, the diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection are diseases or symptoms caused by a heat shock protein 70 (Hsp70). The compound in the present invention is used for overcoming a difficult problem of drug resistance of tumors, improves the effect of tumor treatment, and provides a new medical strategy for clinical tumor treatment.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: September 20, 2022
    Assignee: Institute of Pharmacology and Toxicology Academy of Millitary Medical Sciences P.L.A. China
    Inventors: Wu Zhong, Song Li, Yanqun Zeng, Junhai Xiao, Xinbo Zhou, Zhibing Zheng, Xingzhou Li, Xiaokui Wang
  • Publication number: 20190233390
    Abstract: The present invention provides a compound of a general formula I, a stereomeride, pharmaceutically acceptable salt or a solvate thereof, a preparation method thereof, and usages in preparing medicines for preventing and/or treating diseases or symptoms caused by drug-resistant tumors or drug-resistant bacteria and in preparing medicines for preventing and/or treating diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection. Preferably, the diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection are diseases or symptoms caused by a heat shock protein 70 (Hsp70). The compound in the present invention is used for overcoming a difficult problem of drug resistance of tumors, improves the effect of tumor treatment, and provides a new medical strategy for clinical tumor treatment.
    Type: Application
    Filed: April 9, 2019
    Publication date: August 1, 2019
    Applicant: Institute of Pharmacology and Toxicology Academy of Millitary Medical Sciences P.L.A. China
    Inventors: Wu ZHONG, Song Li, Yanqun Zeng, Junhai Xiao, Xinbo Zhou, Zhibing Zheng, Xingzhou Li, Xiaokui Wang
  • Patent number: 10301279
    Abstract: The present invention provides a compound of a general formula I, a stereomeride, pharmaceutically acceptable salt or a solvate thereof, a preparation method thereof, and usages in preparing medicines for preventing and/or treating diseases or symptoms caused by drug-resistant tumors or drug-resistant bacteria and in preparing medicines for preventing and/or treating diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection. Preferably, the diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection are diseases or symptoms caused by a heat shock protein 70 (Hsp70). The compound in the present invention is used for overcoming a difficult problem of drug resistance of tumors, improves the effect of tumor treatment, and provides a new medical strategy for clinical tumor treatment.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: May 28, 2019
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Wu Zhong, Song Li, Yanqun Zeng, Junhai Xiao, Xinbo Zhou, Zhibing Zheng, Xingzhou Li, Xiaokui Wang
  • Patent number: 10023565
    Abstract: The present invention relates to a compound of formula (I), a stereomeride, pharmaceutically acceptable salt, a solvate or an N-oxide thereof, a medicine composition comprising the compound, a method for preparing the compound, and a usage of the compound in treating diseases related to Hsp70. The diseases are preferably selected from tumors, neurodegenerative diseases, and allogeneic transplantation rejection and infection.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: July 17, 2018
    Assignee: INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA
    Inventors: Wu Zhong, Song Li, Yanqun Zeng, Junhai Xiao, Xinbo Zhou, Zhibing Zheng, Xingzhou Li, Xiaokui Wang, Lili Wang
  • Publication number: 20180044321
    Abstract: The present invention provides a compound of a general formula I, a stereomeride, pharmaceutically acceptable salt or a solvate thereof, a preparation method thereof, and usages in preparing medicines for preventing and/or treating diseases or symptoms caused by drug-resistant tumors or drug-resistant bacteria and in preparing medicines for preventing and/or treating diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection. Preferably, the diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection are diseases or symptoms caused by a heat shock protein 70 (Hsp70). The compound in the present invention is used for overcoming a difficult problem of drug resistance of tumors, improves the effect of tumor treatment, and provides a new medical strategy for clinical tumor treatment.
    Type: Application
    Filed: October 26, 2017
    Publication date: February 15, 2018
    Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Wu ZHONG, Song LI, Yanqun ZENG, Junhai XIAO, Xinbo ZHOU, Zhibing ZHENG, Xingzhou LI, Xiaokui WANG
  • Patent number: 9840489
    Abstract: The present invention provides a compound of a general formula I, a stereomeride, pharmaceutically acceptable salt or a solvate thereof, a preparation method thereof, and usages in preparing medicines for preventing and/or treating diseases or symptoms caused by drug-resistant tumors or drug-resistant bacteria and in preparing medicines for preventing and/or treating diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection. Preferably, the diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection are diseases or symptoms caused by a heat shock protein 70 (Hsp70). The compound in the present invention is used for overcoming a difficult problem of drug resistance of tumors, improves the effect of tumor treatment, and provides a new medical strategy for clinical tumor treatment.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: December 12, 2017
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Wu Zhong, Song Li, Yanqun Zeng, Junhai Xiao, Xinbo Zhou, Zhibing Zheng, Xingzhou Li, Xiaokui Wang
  • Patent number: 9718770
    Abstract: The invention provides a compound of Formula I, an isomer, a pharmaceutically acceptable salt, or a solvate thereof, and use thereof in manufacture of a medicament for preventing and/or treating a drug-resistant tumor or disease or disorder caused by a drug-resistant bacterium, or use thereof in manufacture of a medicament for preventing and/or treating a tumor, a neurodegenerative disease, an allogeneic graft rejection, or an infection-associated disease or disorder; preferably, the tumor, neurodegenerative disease, allogeneic graft rejection, or infection-associated disease or disorder is a disease or disorder caused by Heat shock protein 70 (Hsp70). The compounds of the invention, which are a class of Hsp70 inhibitors having a novel structure and a high activity, solve the problem concerning drug resistance of tumors, enhance the effect of treating tumors, and provide a new medical strategy for treatment of tumors in clinic.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: August 1, 2017
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Wu Zhong, Song Li, Yanqun Zeng, Junhai Xiao, Xinbo Zhou, Zhibing Zheng, Xingzhou Li, Xiaokui Wang
  • Publication number: 20160333002
    Abstract: The present invention relates to a compound of formula (I), a stereomeride, pharmaceutically acceptable salt, a solvate or an N-oxide thereof, a medicine composition comprising the compound, a method for preparing the compound, and a usage of the compound in treating diseases related to Hsp70. The diseases are preferably selected from tumors, neurodegenerative diseases, and allogeneic transplantation rejection and infection.
    Type: Application
    Filed: December 19, 2014
    Publication date: November 17, 2016
    Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Wu ZHONG, Song LI, Yanqun ZENG, Junhai XIAO, Xinbo ZHOU, Zhibing ZHENG, Xingzhou LI, Xiaokui WANG, Lili WANG
  • Publication number: 20160318896
    Abstract: The present invention provides a compound of a general formula I, a stereomeride, pharmaceutically acceptable salt or a solvate thereof, a preparation method thereof, and usages in preparing medicines for preventing and/or treating diseases or symptoms caused by drug-resistant tumors or drug-resistant bacteria and in preparing medicines for preventing and/or treating diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection. Preferably, the diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection are diseases or symptoms caused by a heat shock protein 70 (Hsp70). The compound in the present invention is used for overcoming a difficult problem of drug resistance of tumors, improves the effect of tumor treatment, and provides a new medical strategy for clinical tumor treatment.
    Type: Application
    Filed: December 19, 2014
    Publication date: November 3, 2016
    Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Wu ZHONG, Song LI, Yanqun ZENG, Junhai XIAO, Xinbo ZHOU, Zhibing ZHENG, Xingzhou LI, Xiaokui WANG
  • Publication number: 20160311767
    Abstract: The invention provides a compound of Formula I, an isomer, a pharmaceutically acceptable salt, or a solvate thereof, and use thereof in manufacture of a medicament for preventing and/or treating a drug-resistant tumor or disease or disorder caused by a drug-resistant bacterium, or use thereof in manufacture of a medicament for preventing and/or treating a tumor, a neurodegenerative disease, an allogeneic graft rejection, or an infection-associated disease or disorder; preferably, the tumor, neurodegenerative disease, allogeneic graft rejection, or infection-associated disease or disorder is a disease or disorder caused by Heat shock protein 70 (Hsp70). The compounds of the invention, which are a class of Hsp70 inhibitors having a novel structure and a high activity, solve the problem concerning drug resistance of tumors, enhance the effect of treating tumors, and provide a new medical strategy for treatment of tumors in clinic.
    Type: Application
    Filed: December 18, 2014
    Publication date: October 27, 2016
    Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Wu ZHONG, Song LI, Yanqun ZENG, junhai XIAO, Xinbo ZHOU, Zhibing ZHENG, Xingzhou LI, Xiaokui WANG